• Veriton Pharma Ltd – New company name for Special Products Ltd
  • Posted in Industry News,News Review

  • 02nd Oct 2017

  •   Press release on behalf of Veriton Pharma Ltd Published online: 2/10/17 Veriton Pharma Ltd is announced as the new company name for Special Products Ltd. This name change has occurred both to incorporate the company’s past heritage with its future ambitions to make trusted medicines available for everyday living. The Chief Commercial Officer commented: With the […]

  • Tecfidera® and Tysabri® data show improved outcomes in early MS treatment
  • Posted in News Review

  • 28th Apr 2017

  •   Real-World Data Further Support Efficacy of Dimethyl Fumarate in Newly Diagnosed and Early Switch Patients MS Patients with High Disease Activity Benefit from Early and Continued Natalizumab Treatment. Biogen have announced new real-world data that show treatment with its leading multiple sclerosis (MS) therapies, TECFIDERA® (dimethyl fumarate) and TYSABRI® (natalizumab), early in the course of the disease may […]

  • Study confirms Apomorphine subcutaneous infusion’s established role in PD
  • Posted in News Review

  • 27th Apr 2017

  • Results from the first randomised, controlled trial investigating the efficacy and safety of APO-go®/MOVAPO® (apomorphine) subcutaneous infusion in Parkinson’s disease (PD) patients whose motor symptoms are not controlled by other therapies – the TOLEDO study – were presented during the ‘Emerging Science’ session at the American Academy of Neurology (AAN) Annual Meeting in Boston, USA, […]


Open Access, for medical professionals: Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified. 

We may infrequently send you news from our sponsors which is relevant to the field of neurology, but you can opt out at any time.

See a sample email newsletter here
This website is for medical professionals only.